VKTX Viking Therapeutics Inc

Price (delayed)

$41.65

Market cap

$4.86B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.67

Enterprise value

$4.74B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 1

Viking Therapeutics, Inc. is a clinical-stage biotechnology company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking ...

Highlights
The company's quick ratio has shrunk by 82% YoY and by 19% QoQ
VKTX's equity is down by 49% year-on-year and by 19% since the previous quarter

Key stats

What are the main financial stats of VKTX

VKTX stock price

How has the Viking Therapeutics stock price performed over time
Intraday
1.96%
1 week
41.09%
1 month
22.9%
1 year
66.8%
YTD
18.39%
QTD
6.77%

Financial performance

How have Viking Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$560.02M
Net income
-$534.8M
Gross margin
N/A
Net margin
N/A
Viking Therapeutics's operating income has plunged by 163% YoY and by 12% from the previous quarter
The net income fell by 13% QoQ

Price vs fundamentals

How does VKTX's price correlate with its fundamentals

Growth

What is Viking Therapeutics's growth rate over time

Valuation

What is Viking Therapeutics stock price valuation
P/E
N/A
P/B
11.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 13% since the previous quarter
The P/B is 132% more than the 5-year quarterly average of 5.0 and 61% more than the last 4 quarters average of 7.2
VKTX's equity is down by 49% year-on-year and by 19% since the previous quarter

Efficiency

How efficient is Viking Therapeutics business performance
The ROIC has declined by 44% since the previous quarter
Viking Therapeutics's ROE has decreased by 33% from the previous quarter
VKTX's ROA is down by 27% since the previous quarter

Dividends

What is VKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VKTX.

Financial health

How did Viking Therapeutics financials performed over time
VKTX's current ratio has dropped by 82% year-on-year and by 17% since the previous quarter
The company's quick ratio has shrunk by 82% YoY and by 19% QoQ
Viking Therapeutics's debt is 99% lower than its equity
VKTX's equity is down by 49% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.